Management Change/Compensation - Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 29, 2022

Imago BioSciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40604		45-4915810
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

329 Oyster Point Blvd. 3rd Floor

South San Francisco, California94080

(Address of principal executive offices, including Zip Code)

Registrant's telephone number, including area code: (415)529-5055

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		IMGO		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§ 240.12b-2of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 29, 2022, the Board of Directors of Imago BioSciences, Inc. (the "Company"), appointed Hsiangyi Chiang, the Company's Senior Vice President, Finance, as the Company's principal accounting officer, effective immediately. Ms. Chiang, age 55, has served as the Company's Senior Vice President, Finance, since January 2022, prior to this Ms. Chiang held the role of Vice President, Finance, from February 2021. Prior to joining the Company, Ms. Chiang served as vice president of finance at Blade Therapeutics, Inc. from 2019, and from 2017 to 2019 as the head of finance and accounting at Medeor Therapeutics, Inc. From 2016 to 2017, Ms. Chiang served as vice president of finance, global controller at Establishment Labs Holdings, Inc., and from 2014 to 2016 as senior director and corporate controller at Principia Biopharma, Inc. Laura Eichorn, the Company's Chief Financial Officer, will no longer serve as the Company's principal accounting officer and will continue to serve as the Company's principal financial officer, effectively immediately.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			IMAGO BIOSCIENCES, INC.
Date: September 1, 2022			By:		/s/ Hugh Y. Rienhoff, Jr., M.D.
			Hugh Y. Rienhoff, Jr., M.D.
			Chief Executive Officer